ASND Stock Overview
A biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Ascendis Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$150.99 |
| 52 Week High | US$169.37 |
| 52 Week Low | US$111.09 |
| Beta | 0.54 |
| 1 Month Change | 0.45% |
| 3 Month Change | 16.87% |
| 1 Year Change | 3.39% |
| 3 Year Change | 33.80% |
| 5 Year Change | 17.05% |
| Change since IPO | 701.86% |
Recent News & Updates
Optimistic Investors Push Ascendis Pharma A/S (NASDAQ:ASND) Shares Up 26% But Growth Is Lacking
Mar 13
Ascendis Pharma A/S (NASDAQ:ASND) Yearly Results: Here's What Analysts Are Forecasting For This Year
Feb 15Recent updates
Optimistic Investors Push Ascendis Pharma A/S (NASDAQ:ASND) Shares Up 26% But Growth Is Lacking
Mar 13Ascendis Pharma A/S (NASDAQ:ASND) Yearly Results: Here's What Analysts Are Forecasting For This Year
Feb 15Ascendis Pharma: Danish Blockbuster Hunter
Jan 29
Anticipated YORVIPATH Launch And SKYTROFA Blockbuster Potential Drive Optimism For Future Growth
Nov 27 Expansion in hypoparathyroidism treatment and growth hormone products drives substantial revenue growth, leveraging a robust commercialization strategy.Ascendis Pharma Takes A Big Price Cut On Skytrofa
Sep 05Ascendis Pharma A/S' (NASDAQ:ASND) Share Price Could Signal Some Risk
Jul 20Ascendis Pharma's Ambitious Vision 2030
Jan 11Shareholder Returns
| ASND | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.8% | 0.5% | 5.4% |
| 1Y | 3.4% | -11.9% | 3.6% |
Return vs Industry: ASND exceeded the US Biotechs industry which returned -17.5% over the past year.
Return vs Market: ASND exceeded the US Market which returned -0% over the past year.
Price Volatility
| ASND volatility | |
|---|---|
| ASND Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: ASND has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ASND's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 1,017 | Jan Mikkelsen | ascendispharma.com |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Ascendis Pharma A/S Fundamentals Summary
| ASND fundamental statistics | |
|---|---|
| Market cap | US$8.58b |
| Earnings (TTM) | -US$428.76m |
| Revenue (TTM) | US$412.38m |
21.9x
P/S Ratio-21.1x
P/E RatioIs ASND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASND income statement (TTM) | |
|---|---|
| Revenue | €363.64m |
| Cost of Revenue | €44.26m |
| Gross Profit | €319.38m |
| Other Expenses | €697.47m |
| Earnings | -€378.08m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.32 |
| Gross Margin | 87.83% |
| Net Profit Margin | -103.97% |
| Debt/Equity Ratio | -722.4% |
How did ASND perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/11 10:15 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascendis Pharma A/S is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Michelle Gilson | Canaccord Genuity |
| Alethia Young | Cantor Fitzgerald & Co. |